Responses
Poster Presentations
Rheumatoid arthritis - non biologic treatment
THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks
Compose a Response to This Article
Other responses
No responses have been published for this article.